주요 내용으로 건너 뛰기

Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients

Powered by Translations.com GlobalLink Web Software